ArticleJournal of diabetes research2026
An Integrated Approach Combining Chemical Profiling, Network Pharmacology, and Experimental Validation Is Used to Clarify the Pharmacological Basis of the Yiqi-Tongluo-Huoxue-Mingmu Formula in Diabetic Retinopathy.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAccording to traditional Chinese medical (TCM) principles diabetic retinopathy (DR) is categorized as a type of "Wasting-Thirst Eye Disease." According to TCM, the pathophysiology of DR is primarily attributed to blood stasis, obstructed collaterals, and concurrent Qi and Yin deficiencies. Yiqi-Tongluo-Huoxue-Mingmu Formula (YQMM), a TCM commonly prescribed for DR, has yet to have its active components and underlying molecular mechanisms fully elucidated.
methodsThe therapeutic efficacy of YQMM was assessed in mice with diabetes induced by streptozotocin (STZ). The chemical profiles of YQMM and its absorbed prototype components in vivo were characterized using LC-Q-TOF/MS. After predicting potential targets and pathways using network pharmacology methods and molecular docking, this study validated these computational results through RT-qPCR experiments. To further evaluate the antiproliferative and antiangiogenic effects of YQMM and its active components, HUVECs cultured under high-glucose conditions were used.
resultsThe retinal protective effects of YQMM were observed without significant alterations in systemic blood glucose levels. Chemical analysis identified 142 compounds, with five prototype constituents (caffeic acid, isoferulic acid, daidzin, daidzein, and mirificin) detected in plasma. Network pharmacology indicated 118 shared targets between YQMM and DR, with key nodes including TP53, ESR1, JUN, STAT3, and MAPK1, primarily linked to the AGE-RAGE, PI3K-Akt, and HIF-1 signaling pathways. Molecular docking predictions revealed strong binding affinities between the targets and the compounds, particularly for daidzin. Both in vivo and in vitro experiments confirmed that YQMM and its active components downregulated the expression of core targets and inhibited high glucose-induced endothelial cell proliferation and tube formation.
conclusionYQMM confers its protective benefits against DR via a complex interplay of multiple active ingredients acting on diverse molecular targets and signaling networks. These findings elucidate the chemical and mechanistic basis for the clinical efficacy of YQMM, supporting its further development as a promising therapeutic agent for DR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.